GKOS vs GMED
Glaukos Corporation vs Globus Medical — AI-powered side-by-side comparison
GKOS
Glaukos Corporation
64
Buy
VS
GMED
Globus Medical
71
Buy
| Metric | GKOS | GMED |
|---|
| AI Score |
64
|
71
|
| Price |
$182.70
|
$85.12
|
| P/E Ratio |
-56.00×
|
21.45×
|
| ROE |
-28.6%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
79.1%
|
68.5%
|
| Debt / Equity |
0.15×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
88.3
|
75.9
|
| Beta |
0.762
|
0.954
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for GKOS versus GMED.
GMED leads by 7 points.
GMED scores 71/100 (Buy) versus GKOS at 64/100 (Buy).
GKOS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 41.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 9.9x prices in significant intangible value — Value
- ROE of only -27.1% -- cheap may mean cheap for a reason — Value
- RSI at 88 is in overbought territory — Technical
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical